Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Jason Butler has given his Buy rating due to a combination of factors related to Zevra Therapeutics. The company has successfully launched MIPLYFFA in the U.S. for the treatment of Niemann-Pick Disease Type C, and this launch is progressing better than initially expected. The availability of MIPLYFFA through a specialty pharmacy indicates an efficient rollout process.
Additionally, Zevra's patient support program, AmplifyAssist, is likely to enhance patient access to MIPLYFFA by providing assistance with insurance, co-pay, and therapy management. The steady increase in prescription enrollments and the positive progress in securing reimbursement approvals suggest a strong market response. Butler's financial projections for the company, including the anticipated monetization of the Priority Review Voucher, further support his optimistic outlook for Zevra's stock.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.